Trials Open to Enrollment

AIDS Clinical Trials: New Trials Open to Enrollment

hftp://www.actis.org/actinewl.html

SA Pilot Study to Determine the Effect of Acyclovir Treatment for Herpes Simplex Virus
(HSV) Infection on Peripheral Blood HIV Viral Load. NIAID DATRI 020. Drug: Acyclovir.
The purpose of this Division of AIDS Treatment Research Initaitive study is (part A) to evaluate
the impact of HSV suppression with acyclovir (ACV) on HIV burden in patients with
asymptomatic HSV infection and at high risk for HSV reactivation; and (part B) to characterize the
change in plasma HIV RNA levels and other measures of HIV burden during and after a 10 day
course of ACV treatment for acute HSV infection. For more information, view the Protocol
Database record.
SA Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and
Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the
Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3. FDA 232C. Drug:
Adefovir dipivoxil.
The purpose of this Gilead Sciences sponsored study is to evaluate the anti-HIV activity, safety,
and tolerance of adefovir dipivoxil (bis-POM PMEA) in combination with standard antiretroviral
therapy for 48 weeks. Patients are randomized to receive either adefovir dipivoxil or placebo daily
for 24 weeks, after which all patients will receive open-label drug for an additional 24 weeks. Study
drug is administered in combination with a current antiretroviral regimen for the entire 48 weeks.
For more information, view the Protocol Database record.
Q A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered
Intrathecally to Cancer and AIDS Patients With Chronic Pain. FDA 256A. Drug: SNX-111.
The purpose of this Neurex Corporation sponsored study is to determine whether different doses of
SNX-111 are safe and effective in controlling severe, chronic pain in cancer and AIDS patients.
Patients are randomized to receive SNX-111 or placebo via external pump and an intrathecal
catheter (thin tube inserted into the spinal canal). For more information, view the Protocol
Database record.
~ Study of the Safety and Effects of Two Doses of SPC3, Administered Daily Intravenously in
HIV-1 Seropositive Patients. FDA 257A. Drug: SPC3.
The purpose of this Columbia Research Laboratories sponsored study is to assess the effects of
two doses of synthetic peptide construction 3 (SPC3) on HIV-1 plasma levels (as measured by
kNA PCR Amplicor)and on lymphocyte subsets in patients with initial viral load above 10000
copies/ml. To study the safety of SPC3 and the kinetics of HIV-1 plasma level changes. For more
information, view the Protocol Database record.
O The Antiviral Effect of Switching From Hard Capsule Saquinavir to the Soft Gelatin
Capsule of Saquinavir Versus Switching to Indinavir After 1 Year of Saquinavir Use. NIAID
ACTG 333. Drugs: Saquinavir mesylate, Indinavir sulfate.
The purpose of this AIDS Clinical Trials Group study is to determine, in HIV-infected patients,
whether switching to a new soft gelatin capsule formulation of saquinavir or to indinavir following
prolonged use of the original hard capsule formulation of saquinavir results in an acute decrease in
plasma HIV RNA. For more information, view the Protocol Database record.

7 of 10

03/17/97 15:07:11